A significant step forward in asthma care is unfolding in India! Bedfont® Scientific Limited, a global leader in breath analysis with nearly 50 years of experience, has joined forces with Rbeck Healthtech Private to make Fractional exhaled Nitric Oxide (FeNO) testing more readily available throughout India. Rbeck Healthtech Private, a distributor specializing in pulmonology, cardiology, and rehabilitation equipment, will now offer the innovative NObreath® device.
This collaboration is particularly crucial because India bears a substantial portion of the global asthma burden, approximately 13.1%. Improving access to diagnostic tools like the NObreath® is therefore vital. But what exactly is FeNO testing, and why does it matter?
The NObreath® measures FeNO levels in exhaled breath. These levels are a key indicator of type 2 airway inflammation, a common characteristic of asthma. By providing clinicians with clearer insights into airway inflammation, FeNO testing can lead to more personalized and effective treatment plans.
Jason Smith, CEO of Bedfont®, stated that this partnership is a significant milestone in their mission to make precision asthma care accessible worldwide. He highlighted the fact that a large number of asthmatic individuals in India remain undiagnosed or undertreated. This is where it gets interesting: the Global Asthma Report 2022 underscores the urgent need to expand FeNO testing accessibility in the region, potentially saving lives.
Related Developments:
- Bedfont® Scientific Limited is also expanding its reach by bringing respiratory and gastrointestinal diagnostic solutions to Saudi Arabia.
- They've partnered with Aerosol Medical Systems to increase FeNO testing access in Latin America.
- A new partnership with Geratherm® Group is also in the works.
Asthma: A Chronic Condition
It's important to remember that asthma is a chronic lung disease, meaning it currently has no cure. However, with the right diagnosis and treatment, individuals with asthma can live normal lives.
What do you think? Do you believe that increased access to FeNO testing will significantly impact asthma management in India? Share your thoughts in the comments below!
